Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
IPO Year:
Exchange: NYSE
Website: https://www.elevancehealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/20/2026 | $498.00 | Hold → Buy | Deutsche Bank |
| 4/29/2026 | $435.00 | Neutral → Buy | BofA Securities |
| 4/8/2026 | $345.00 | In-line | Evercore ISI |
| 2/3/2026 | $358.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 1/8/2026 | $425.00 | Peer Perform → Outperform | Wolfe Research |
| 12/19/2025 | $320.00 | Buy → Hold | Deutsche Bank |
| 10/14/2025 | Neutral | Goldman | |
| 7/21/2025 | Buy → Hold | Argus | |
| 7/18/2025 | $310.00 | Outperform → Market Perform | Leerink Partners |
| 4/15/2025 | $529.00 | Outperform → Neutral | Robert W. Baird |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Deutsche Bank upgraded Elevance Health from Hold to Buy and set a new price target of $498.00
BofA Securities upgraded Elevance Health from Neutral to Buy and set a new price target of $435.00
Evercore ISI initiated coverage of Elevance Health with a rating of In-line and set a new price target of $345.00
RBC Capital Mkts downgraded Elevance Health from Outperform to Sector Perform and set a new price target of $358.00
Wolfe Research upgraded Elevance Health from Peer Perform to Outperform and set a new price target of $425.00
Deutsche Bank downgraded Elevance Health from Buy to Hold and set a new price target of $320.00
Goldman initiated coverage of Elevance Health with a rating of Neutral
Argus downgraded Elevance Health from Buy to Hold
Leerink Partners downgraded Elevance Health from Outperform to Market Perform and set a new price target of $310.00
Robert W. Baird downgraded Elevance Health from Outperform to Neutral and set a new price target of $529.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
Fastest customizable press release news feed in the world
2Q 2026 operating revenue of $49.8 billion, up 0.8% from 2Q 2025 2Q 2026 diluted EPS1 of $6.71 and adjusted diluted EPS2 of $7.45; results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit FY 2026 diluted EPS1 guidance raised to at least $20.10; adjusted diluted EPS2 guidance raised to at least $27.00, reflecting strong second quarter operating results Accelerating targeted investments in capabilities that lower healthcare costs, simplify the member and provider experience, and strengthen Carelon's integrated solutions FY 2026 operating cash flow guidance raised to at least $6.0 billion Elevance Health, In
Elevance Health (NYSE:ELV) will release second quarter 2026 financial results on July 15, 2026, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-391-9853 - No Access Code (Domestic Replay) 203-369-3269 - No Access Code (International Replay) The call will be available through a live webcast at www.elevancehealth.com under the "Investors" link. You may also acces
Research finds arbitration awards for certain planned procedures are often far higher than typical in-network payment rates The No Surprises Act was created to protect patients from unexpected medical bills. While those patient protections are working, new research from the Elevance Health Public Policy Institute suggests that the law's payment dispute process is producing unexpected results for some planned medical procedures. The findings come as federal IDR volume has grown far beyond initial projections, raising concerns that a process intended as a limited payment-dispute backstop is increasingly contributing to higher out-of-network costs. The study examined more than 7,300 paym
Thomas Carr Howe Middle School today celebrated the unveiling of a newly transformed fitness and strength training space made possible through a partnership with Elevance Health and the Impact Fitness Foundation (IFF). The project marks the fifth consecutive year that Elevance Health and IFF have invested in Indianapolis schools through community fitness initiatives connected to the Elevance Health Women’s Fort Myers Tipoff, a premier collegiate basketball tournament that celebrates the impact of women in sports. More than 40 Elevance Health volunteers worked alongside representatives from the Impact Fitness Foundation to renovate the school’s fitness and athletic training areas, creati
Elevance Health today announced advancements in how it helps streamline clinical review and create a simpler, faster, and more connected experience for care providers and members through Health OS. Health OS is Elevance Health’s secure data platform designed to connect health information across electronic health records (EHRs), labs, and health information exchanges, helping support more informed and timely clinical decisions while reducing administrative burden for care providers. By connecting with healthcare data systems, including Epic’s Payer Platform, Health OS helps reduce manual steps and deliver clearer clinical insights. "Health OS represents a foundational shift in how we app
Strategic investments support more than 40,000 housing units and advance whole health outcomes for communities across the countryElevance Health (NYSE:ELV) today announced it has invested $640 million in affordable housing over the past five years, building on more than $1 billion invested over nearly two decades. These investments reflect the company's continued commitment to addressing social drivers of health, helping lower the total cost of care, and expanding access to safe, stable, and affordable housing.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617980738/en/Elevance Health has invested more than $1 billion across ap
Delivers proactive guidance and coordinated care to help people better manage their health Across the country, three in four adults are living with at least one chronic condition. Elevance Health is helping people manage chronic conditions by creating more personalized, connected experiences that make it easier to understand care, stay on track, and know what to do next. Elevance Health is working to simplify that experience by using data, digital tools, and proactive outreach to connect the people it serves to the support they need when they need it, through services offered through its health plans or its healthcare services business, Carelon. "Managing a chronic condition can be ch
Elevance Health is advancing its commitment to improving healthcare access by addressing one of healthcare's most pressing challenges: the digital divide. Through innovative programs like Get Connected for Health and services offered by CareBridge, a subsidiary of Elevance Health, the company is helping ensure that individuals - especially those in underserved communities - have the tools, connectivity, and support needed to help them better manage their healthcare. Access to digital health tools has become increasingly essential in today's healthcare environment. Yet millions of Americans still lack reliable internet access, appropriate devices, or the digital literacy required to fully
By combining clinical programs, digital innovation and community partnerships, the company aims to improve wellbeing and reduce crises, ER visits and total cost of care for mental health Despite growing awareness, mental health concerns remain difficult to navigate and often lead to avoidable crises, costly emergency room visits, and long-term strain on individuals, families, and an already overburdened healthcare system. With nearly one in five Americans experiencing a diagnosable mental health condition each year, the need for funding and systemic improvement has never been greater. That's why Elevance Health is focused on addressing some of the most urgent challenges in mental health
Annual program honors practices delivering highest quality care and exceptional patient experience in Elevance Health's affiliated health plans across the country Elevance Health, along with its affiliated health plans, today announced 45 distinguished medical practices and health systems to be honored in its annual Care Provider Recognition Program. The program spotlights the top one percent of primary care providers in Elevance Health's nationwide affiliated health plan network of about 7,200 value-based care and evaluated provider partners. The recognition highlights primary care providers who exhibit excellence in delivering high-quality, coordinated care for members across Elevance
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
10-Q - Elevance Health, Inc. (0001156039) (Filer)
8-K - Elevance Health, Inc. (0001156039) (Filer)
11-K - Elevance Health, Inc. (0001156039) (Filer)
11-K - Elevance Health, Inc. (0001156039) (Filer)
8-K - Elevance Health, Inc. (0001156039) (Filer)
8-K - Elevance Health, Inc. (0001156039) (Filer)
10-Q - Elevance Health, Inc. (0001156039) (Filer)
8-K - Elevance Health, Inc. (0001156039) (Filer)
PX14A6G - Elevance Health, Inc. (0001156039) (Subject)
DEFA14A - Elevance Health, Inc. (0001156039) (Filer)
Live finance-specific insights
2Q 2026 operating revenue of $49.8 billion, up 0.8% from 2Q 2025 2Q 2026 diluted EPS1 of $6.71 and adjusted diluted EPS2 of $7.45; results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit FY 2026 diluted EPS1 guidance raised to at least $20.10; adjusted diluted EPS2 guidance raised to at least $27.00, reflecting strong second quarter operating results Accelerating targeted investments in capabilities that lower healthcare costs, simplify the member and provider experience, and strengthen Carelon's integrated solutions FY 2026 operating cash flow guidance raised to at least $6.0 billion Elevance Health, In
Elevance Health (NYSE:ELV) will release second quarter 2026 financial results on July 15, 2026, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-391-9853 - No Access Code (Domestic Replay) 203-369-3269 - No Access Code (International Replay) The call will be available through a live webcast at www.elevancehealth.com under the "Investors" link. You may also acces
1Q 2026 operating revenue of $49.5 billion, up 1.5% from 1Q 2025 1Q 2026 diluted EPS1 of $8.00; adjusted diluted EPS2 of $12.58 driven by strong operating results and ~$1 per share of non-recurring investment income FY 2026 diluted EPS1 guidance to be at least $19.85, including the Company's estimate of the financial impact for the CMS matter FY 2026 adjusted diluted EPS2 guidance raised to at least $26.75, supported by underlying business strength, actions to reduce medical costs, and increased visibility Reaffirm FY 2026 operating cash flow of at least $5.5 billion, inclusive of potential cash payments for the CMS matter Returned $1.5 billion of capital to shareholders in
Elevance Health (NYSE:ELV) will release first quarter 2026 financial results on April 22, 2026, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-391-9853 - No Access Code (Domestic Replay) 203-369-3269 - No Access Code (International Replay) The call will be available through a live webcast at www.elevancehealth.com under the "Investors" link. You may also acces
4Q 2025 operating revenue of $49.3 billion; FY 2025 of $197.6 billion 4Q 2025 diluted EPS1 of $2.47; adjusted diluted EPS2 of $3.33 FY 2025 diluted EPS1 of $25.21; adjusted diluted EPS2 of $30.29 Projected FY 2026 GAAP diluted EPS1 to be at least $22.30 Projected FY 2026 adjusted diluted EPS2 to be at least $25.50 Returned $4.1 billion of capital to shareholders in 2025 Reaffirming long-term earnings algorithm; recalibrating segment margin targets Elevance Health, Inc. (NYSE:ELV) reported fourth quarter and full year 2025 results. "Elevance Health delivered fourth quarter results in line with our outlook, reflecting disciplined execution in a dynamic environment. As
Elevance Health (NYSE:ELV) will release fourth quarter and full year 2025 financial results on January 28, 2026, at 6:00 a.m. Eastern Standard Time ("EST"). Management will review these results and its outlook during a conference call at 8:30 a.m. EST that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 888-566-0046 - No Access Code (Domestic Replay) 203-369-3677 - No Access Code (International Replay) The replay will be available from 11:30 a.m. EST on January 28, 2026, until the end of the day on Februar
AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a+" (Excellent) of the core Blue Cross Blue Shield (BCBS)-branded insurance subsidiaries of Elevance Health, Inc. (Elevance) (Indianapolis, IN) (NYSE:ELV), as well as most of its non-Blue-branded subsidiaries. In addition, AM Best has upgraded the FSR to A (Excellent) from A- (Excellent) and the Long-Term ICR to "a+" (Excellent) from "a-" (Excellent) of Wellpoint Life and Health Insurance Company and Wellpoint West Virginia, Inc. These companies collectively are referred to as Anthem Health. At the same time, AM Best has affirmed the Long-Term ICR of "bbb+"
Executing with discipline to improve affordability and elevate the member experience 3Q 2025 operating revenue of $50.1 billion, up 12.0% from 3Q 2024 3Q 2025 diluted EPS1 of $5.32; adjusted diluted EPS2 of $6.03 Reaffirm FY 2025 benefit expense ratio and adjusted diluted EPS guidance of approximately 90.0% and approximately $30.00, respectively Returned $3.3 billion of capital to shareholders year-to-date Elevance Health, Inc. (NYSE:ELV) reported third quarter 2025 results. "Our third quarter results were in line with expectations and reflect disciplined execution across Elevance Health. In a dynamic healthcare environment, we're focused on advancing affordability and ele
Elevance Health (NYSE: ELV) will release third quarter 2025 financial results on October 21, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-391-9853 - No Access Code (Domestic Replay) 203-369-3269 - No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on October 21, 2025, until the end of the day on November 21, 2025. Th
2Q 2025 operating revenue of $49.4 billion, up 14.3% from 2Q 2024 2Q 2025 diluted EPS1 of $7.72; adjusted diluted EPS2 of $8.84 Revising FY 2025 adjusted diluted EPS guidance to approximately $30.00 Returned $2.0 billion of capital to shareholders year-to-date Elevance Health, Inc. (NYSE:ELV) reported second quarter 2025 results. "In the second quarter, Elevance Health made meaningful progress in delivering an experience that is simple and personal to those we serve, while advancing our efforts to enhance efficiency across the healthcare system. We are updating our outlook to reflect elevated medical cost trends in ACA and slower rate alignment in Medicaid. While the exter
Live Leadership Updates
Elevance Health, Inc. (NYSE:ELV) today announced management changes designed to simplify decision-making and strengthen execution across Carelon and Health Benefits. As part of these changes, Mark Kaye, Executive Vice President and Chief Financial Officer, will expand his responsibilities to include oversight of Carelon, the Company's healthcare services operations including pharmacy services, behavioral health, value-based care, and care delivery capabilities. Carelon plays a critical role in advancing the Company's strategy to lower the cost of care. Carelon's operating priorities and client commitments remain unchanged. Felicia Norwood, Executive Vice President and Chief Health Benef
The board of directors of Elevance Health (NYSE:ELV) today announced the appointment of Amy Schulman, a recognized healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will serve on the Audit and Finance Committees, contributing deep expertise in healthcare innovation, regulatory strategy, and value creation across complex, global enterprises. This appointment reflects Elevance Health's ongoing board refreshment strategy to ensure diverse, independent, and future-focused leadership that aligns with the company's long-term strategy and stakeholders' priorities. "Amy's record of driving innovation, disciplined investment, an
Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe
Nationally Recognized Healthcare Policy Leader Adam Herbst Strengthens the Firm's Regulatory Capabilities for Clients Across the Post-Acute, Aging and Long-Term Care Sectors Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Adam S. Herbst has joined the firm as a healthcare partner in New York. Most recently, Herbst served as the New York State Department of Health's Deputy Commissioner for Aging and Long Term Care. He is the ninth healthcare partner to join the firm in 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030758975/en/Adam Herbst (Photo: Business Wire) In joining Sheppard Mullin's industry-l
Performant Financial Corporation (NASDAQ:PFMT) (Performant), primarily operating as Performant Healthcare Solutions, a leading provider of technology-enabled payment integrity, eligibility, and related analytics services, is proud to announce the appointment of Dr. Shantanu Agrawal, M.D. to its Board of Directors. Dr. Agrawal brings a wealth of expertise and experience in healthcare policy and payment integrity. As Chief Health Officer at Elevance Health (NYSE:ELV), Dr. Agrawal oversees the whole health strategy, including medical policy and clinical quality, as well as the community health strategy and Elevance Health Foundation. Prior to Elevance Health, Dr. Agrawal held numerous execut
Paragon doubles revenues and increases the number of infusion centers by 400% during Peak Rock's ownership AUSTIN, Texas, Jan. 5, 2024 /PRNewswire/ -- An affiliate of Peak Rock Capital ("Peak Rock"), a leading middle-market private investment firm, announced today it has signed a definitive agreement for the sale of Paragon Healthcare, Inc. ("Paragon" or the "Company") to Elevance Health (NYSE:ELV). Paragon is a leading provider of ambulatory and home infusion services as well as specialty pharmacy services. The Company provides comprehensive, high quality infusion services to patients with chronic health conditions and those in need of post-acute care. Headquartered in Plano, Texas, with m
Mark Kaye named Executive Vice President, Chief Financial Officer Elevance Health (NYSE:ELV) announced today that John Gallina will retire from his role as executive vice president and CFO later this year. Mark Kaye has been named executive vice president and CFO and will serve as a member of the company's executive leadership team, reporting directly to Gail K. Boudreaux, President and CEO. Kaye will serve as CFO Designate from September 6 to November 1, 2023, when he will assume full responsibility for the role. Gallina will remain with Elevance Health serving as Special Advisor to the CEO following his retirement as CFO to ensure a seamless transition. Gallina's distinguished career
Duo Health, a new type of medical group purpose-built to care for patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD) in value-based collaborations with local providers, announced the appointment of Raul Smith as Chief Financial Officer. Smith brings nearly two decades of financial leadership and growth-stage executive experience to the role, where he will lead Duo Health's strategic financial operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230803074729/en/(Photo: Business Wire) Prior to joining Duo Health, Smith served in senior roles at Elevance Health Inc. (NYSE:ELV) including President o
PLANTATION, Fla., Aug. 12, 2022 /PRNewswire/ - Akumin Inc. (NASDAQ:AKU) (TSX:AKU) ("Akumin" or the "Company") provided a business update and announced the termination of employment of its Chief Financial Officer, William Larkin and the appointment of David Kretschmer as Interim Chief Financial Officer, effective today. The Company has implemented a transformation program with initiatives focused on its operations, growth, and capital. These initiatives are intended to support the Company's objectives with respect to patient access and experience, customer and partner engagement, financial sustainability, and employee well-being. The Company is receiving support from a globally recognized tr
This live feed shows all institutional transactions in real time.
SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)
SC 13G - Elevance Health, Inc. (0001156039) (Subject)
SC 13G - Elevance Health, Inc. (0001156039) (Subject)
SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)